Life Sciences Archive » May, 2025

Life Sciences - May, 2025

282 articles

• Pharma Co. Hid Cancer Study Method Problems, Investor Claims
• $5.2M Generic Drug Price-Fixing MDL Deal Gets Final OK
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• Crowdfunding, Reg A Deals Grow Slowly As SEC Weighs Ideas
• TopCo Settles Suit Over Cough Syrup Billed As 'Non-Drowsy'
• Congress Must Restore IP Protection To Drive US Innovation
• ITC Issues Import Block On Ascletis Liver Disease Drugs
• How Focus On Menopause Care Is Fueling Innovation, Access
• The BigLaw Settlements Are About Risk, Not Profit
• Generic-Drug Makers Near Exit From Depo-Provera MDL
• DLA Piper Adds Healthcare Regulatory Atty In DC Office
• Former Pfizer Atty, Motley Rice Adviser Joins DiCello Levitt
• Neb.'s Cannabis Regulatory Void Poses Operational Risks
• AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case
• CMS Seeks Hospital Responses On Gender Dysphoria Care
• Monsanto-Funded Researcher Influenced Panel, Jury Hears
• Express Scripts Says Arkansas Can't Ban PBM Pharmacies
• Delaware Justices Asked To Review Corporate Law Rework
• Judge Favors Vanda But Seeks Deal Over Drug Approval
• Ex-USPTO Solicitor Says He's Against Squires Nomination
• Drugstores Say Texas Flouted Rules To Update Pharmacy Regs
• Ex-United Therapeutics Exec Can't Dodge IP Suit
• Cochlear Implant Rivals Call Truce Ahead Of UPC Ruling
• Courts Must Revitalize Robust Claim Construction
• What Gene Findings Mean For Asbestos Mesothelioma Claims
• Brazilian Jiujitsu Makes Me A Better Lawyer
• 16 States Sue Trump Admin Over Cuts To Science Grants
• 5 Federal Circuit Clashes To Watch In June
• Regeneron Urges Judge In FCA Kickback Suit To Set Trial Date
• Fla. Judge Told Pharma Co. Rival Also Stole Trade Secrets
• Fed. Circ. Lets Stewart Revise Longhorn Sanctions Order
• 3rd Circ. Pauses J&J Unit Appeal In Talc Study Libel Case
• Drugmaker LIVation Fights Novo Nordisk's Trademark Claims
• Class Suit Against AI Drugmaker Back On After Mediation Fails
• Indian Pharma Co. Hit With Patent Suit Over Fennec's Cancer Drug
• Mallinckrodt Investors Get Initial OK For $5.5M Settlement
• Singapore's Quadria Closes $1B-Plus Healthcare Fund
• Mich. School, Student GOP Club Spar In Free Speech Suit
• Vt. Judge To Order Release Of Harvard Researcher
• Fed. Circ. In April: Introducing New Evidence During IPR
• Checkpoint Pharma Sued For Docs On $355M Merger Plan
• FDA Commissioner Speech Suggests New Vision For Agency
• China Can't Duck PPE Hoarding Claims By Fla. Medical Pros
• Freshfields Gains New Tech M&A Leadership From Debevoise
• Kirkland Hires 3 M&A Partners From Skadden
• Cooley Adds Ex-FDA Attorney To DC Life Sciences Group
• Bluebird Bio Beats Investor Suit Over FDA Cancer Warning
• Philips Can't Nix Suit Over Sleep Machine Catching Fire
• Bayer, Monsanto On Hook For $611M Roundup Cancer Awards
• Bankrupt 23andMe To Delist Stock After Regeneron Deal
• DOJ Export Declination Highlights Self-Reporting Benefits
• Feds No Longer Advise COVID Shot For Kids, Pregnant Adults
• AG Watch: Texas Expands Use Of Consumer Protection Laws
• Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker
• Justices Deny Food Wrapping Co.'s Prior Art Petition
• Law360 Reveals Titans Of The Plaintiffs Bar
• Fed. Circ. Lifts Stay Against MSN In Entresto Appeal
• Meta, App Maker Flo Can't Escape All Of Privacy Class Action
• LegitScript Can't Use 'Unclean Hands' To Ax Antitrust Case
• Seattle Cancer Center Inks $11.5M Class Data Breach Deal
• Fed. Circ. Dings PTAB Decision Upholding X-Ray Patent
• Ex-McKinsey Exec Sentenced For Obstructing Purdue Probe
• Power To The Paralegals: An Untapped Source For Biz Roles
• Trump Admin Must Restore 'Censored' Harvard Docs' Articles
• FTC Probing Alcon's $430M Lensar Deal
• Biotech Insider Traded On $3.5B Novartis Deal, Feds Say
• A Path Forward For Colo. Pot Products After Failed Safety Test
• Class Of Health Plans Certified In Avandia Marketing MDL
• My So-Called Retirement: Some IP Lawyers Just Can't Quit
• Cooley Hires 'Next-Gen' Boston Labor & Employment Partner
• Ballard Spahr Adds IP Transactions Pro From DLA Piper
• Insulet Foe Rips $30M Atty Fee Ask As 'Over-Lawyered'
• Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents
• Senators Unveil DNA Privacy Bill Amid 23andMe's Ch. 11 Sale
• Calif. Docs Bring FDA Stem Cell Regulation Fight To Top Court
• Justices Urged To Undo Denial Of Fast Track For Gastro Drug
• EpiPen Direct Buyers, Mylan Get Final OK On Antitrust Deal
• Manufacturer Seeks Over $19M In Beryllium Release Coverage
• Judge Asks If DEI Is Now 'Homogeneity, Inequity And Exclusion'
• Playing Poker Makes Me A Better Lawyer
• Conn. AG Targets 'Bootleg' Weight Loss Drug Sellers
• What EU 'Killer Acquisition' Study Means For Pharma Deals
• Sanofi To Acquire Goodwin-Led US Biotech Biz For $470M
• FTC Urges 8th Circ. Not To Pause In-House PBM Case
• Squires Talks Fortress, PTAB Invalidations In Senate Hearing
• 9th Circ. Judge Asks If Apple's Watch Updates 'Ice Out' Rivals
• Judge Mulls National Scope Of Bid To Restore COVID Grants
• AbbVie Gets Victory In Allergan Shareholder Suit Upheld
• GOP FTC Renews Calls For Orange Book Patent Delistings
• Legal Risks For Providers Discussing Psychedelic Therapies
• Kronos Bio Shareholder Says Sale Unfairly Benefits Execs
• Device Maker Who Evaded Tax Gets 2 Years In Prison
• Walgreens Ducks False Ad Suit Over Mucus Relief Meds
• Law School's Missed Lessons: Becoming A Firmwide MVP
• Flo Users Get Class Cert. In Google, Meta Data-Sharing Suit
• Barclays Officials Beat Shareholder's Suit At NY High Court
• Novo Fights To Keep Info Bid In $800M Fraud Dispute Alive
• Cancer Drug Co. Beats Investor Suit Over FDA Rejection
• Medical Organizations Sue Feds For Removing Health Data
• Medical Supply Co. Faces Ga. Suit Over Unwanted Texts
• Moderna Says Order To Narrow Vax IP Case Should Stay
• Creditors Win Fight Against Insider Releases In Azzur Ch. 11
• Biotech Stockholders Challenge Director Pay Levels In Del.
• Sales Exec Admits Role In $70M Brain Scan Kickback Scheme
• Trade Secrets Would Likely See Court Protection From GenAI
• A Breakdown Of Trump's Order On Drug Pricing
• Former Kite Pharma Exec Alleges Gender Bias, Retaliation
• SEC's 'Shadow Trading' Win Should Be Tossed, 9th Circ. Told
• Ex-CTA Worker Can Take Vaccine Bias Claim To Trial
• Feds Get Early Win In Drugmakers' Suit Over 340B Rebates
• Bluebird Beats Patent Case Over Blood Disease Therapies
• Biotech Services Company Files Ch. 11 With $60M In Debt
• Cosmetic Co. Considerations As More States Target PFAS
• Wachtell-Led Regeneron To Buy 23andMe, Gaining User Data
• Covington Corporate M&A Atty Moves To Clifford Chance
• USPTO Seeks Input On Guidelines For Fighting Online Fakes
• IPO Pipeline Restarts As Tariff-Related Volatility Eases
• J&J Unit Hit With $147M Verdict In Catheter Antitrust Suit
• Biotech Co. Hit With Investor Suits Over Cancer Drug Launch
• Parents Sue Colgate Over Alleged Dangers Of Fluoride Rinse
• Bank Balks At Nostrum Ch. 11 Sale Over Drug Disposal Issue
• Illumina Accuses Ex-Workers' Co. Of Infringing Gene Tech IP
• Feds Want Ex-McKinsey Exec To Serve Time For Obstruction
• Del. Bill Reflects Nat'l Tug-Of-War Between Cannabis, Alcohol
• Ex-Womble Bond Atty Heads To Chicago With Shook Hardy
• 23 States Win Order Halting Billions In HHS Public Health Cuts
• Cooley, Goodwin Build BioMarin's $270M Inozyme Buy
• Trump Admin Settles Vaccine Contract Info Suit For $10K
• $38M Law Firm Settlement Highlights 'Unworthy Client' Perils
• J&J Unit's Economist Rips Rival's $147M Antitrust Damage Bid
• 7th Circ. Weighs AbbVie Whistleblower's Drug Marketing Suit
• Novo's Real Target In Doc Bid Is $800M Arbitration, Co. Says
• UMich Protesters Say Lives 'Upended' By Campus Bans
• Maintaining Legal Compliance For GenAI In Life Sciences
• Trending At The PTAB: The Influence Of Litigation Arguments
• Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs
• Harvard Researcher Held By ICE To Be Returned To Mass.
• Amarin Tells Justices Hikma Has Gotten Far Ahead Of Itself
• Teaching Business Law Makes Me A Better Lawyer
• Curaleaf And Ex-VP In Settlement Talks, Court Told
• Davis Wright Adds Longtime Knobbe Martens IP Duo In Seattle
• Regeneron Wins $271.2M In Amgen Antitrust Suit
• Actinium Faces Derivative Suit Over FDA Application Claims
• J&J Unit's Catheter Policy Stopped Free-Riding, Jury Told
• RJ Reynolds Can Keep Trial Win In Engle Case, Court Says
• Integra Brass Face Investor Suit Over FDA Compliance Lapses
• Regeneron-Amgen Trial Goes To Jury With An Extra Day
• Sage Therapeutics Brass Sued Over Drug Candidate Claims
• 2nd Circ. Has Tough Questions On Nixing Medical Imaging Award
• 10th Circ. Chilly To Biotech's SEC Asset Freeze Challenge
• Harvard Researcher Charged With Smuggling Amid ICE Case
• Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax
• Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal
• D'Oh! Kimberly-Clark Can't Keep Wage Suit In Federal Court
• Deregulation Memo Presents Risks, Opportunities For Cos.
• Eckert Seamans Enters NYC With 11 Hawkins Parnell Attys
• Biotech Firm Verax Tells Court Eviction Could End Company
• RFK Jr. Defends HHS Cuts, Pledges To 'Spend Smarter'
• Law School's Missed Lessons: Mastering Discovery
• Biogen Sues Ex-Collaborator Over Rights To Drug Tech
• Asterisk Doesn't Save CVS In Sanitizer Row, 9th Circ. Told
• PTAB Ramps Up Fintiv Denials After Withdrawal Of Memo
• Magistrate Judge Cuts Defendants In J&J Talc Unit Fraud Suit
• Becton Dickinson Sues Baxter Over Infusion Pump Patents
• Regeneron-Amgen Drug Bundling Trial Heads Toward Jury
• 10x Genomics, Bruker Strike Deal After $31M Patent Verdict
• NIH Letters Ending Grants Lack Factual Support, Judge Says
• PBMs Get Bipartisan Bashing At Hearing On Drug Costs
• Cancer Centers Want Fed. Circ. To Rehear Antibody IP Fight
• Former J&J, Moderna Exec Joins Goodwin Procter In Boston
• Maneuvering The Weeds Of Cannabis Vertical Integration
• Express Scripts, FTC Say Defamation Suit 'Should Proceed'
• W.Va. High Court Declines 4th Circ. Request For Opioid Input
• Missouri Hit With Sanctions In Generics Price-Fixing Fight
• Fed. Circ. Erases MIT, Broad CRISPR Win In Conception Fight
• Mass. Court Says NIH Grant Disruption Suit Is In The Right Place
• UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit
• AGs Call Sandoz Deal's Consumer-Side Benefits 'Illusory'
• Fla. Pharmacy Beats Novo Nordisk Suit Over Ozempic 'Copies'
• 20 AGs Suing HHS Move to Halt Cuts At 4 Affected Agencies
• The IRS Shouldn't Go To War Over Harvard's Tax Exemption
• Fed. Circ. Won't Revive Sydnexis Eye Drop Patents
• Will Justices Finally Rein In Universal Injunctions?
• J&J Co.'s Catheter Policy Limited Choices, Doc Testifies
• Pathology Lab Urges 8th Circ. Not To Revive Antitrust Claims
• Private Fundraising Takes Hit Amid Volatile Backdrop
• More Conn. Dentists Reach Kickback Deals With AG, Feds
• Souter's Clerks Remember Him As Humble, Kind And Caring
• Insulet Seeks $30M In Atty Fees, Costs After Trade Secret Win
• Hiker And 'Raconteur': Atty Recalls 50-Year Bond With Souter
• A Look At David Souter's Most Significant Opinions
• Justice Souter Was An Unexpected Force Of Moderation
• UK-US Trade Deal Needs Work On Pharma And IP, Pros Say
• Playing Guitar Makes Me A Better Lawyer
• Retired Supreme Court Justice David Souter Dies At 85
• J&J Unit's Encryption Tech Stalled Rival, Antitrust Jury Told
• AMAG Inks $7.5M Deal In Suit Over Preterm-Birth Drug
• Ruling Over Expired Bard Patent Causes Split, Justices Told
• Colo. Court Sets Next Toxic Tort Bellwether For January
• Counterfeit Goods Hit $467B Globally In 2021, Report Says
• Court Upholds CMA's £99M Thyroid Drug Price Fines
• Bayer Says Wash. Law, FDA Preempt IUD Defect Allegations
• Albertsons Says Counties Have 'Paradoxical Status' In MDL
• Fed. Circ. Weighs If Expert's Testimony Justifies Spine IP Loss
• Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL
• 3rd Circ. Rejects Challenge To Medicare Drug Price Program
• Judge Asks DOJ To Define DEI In Health Grant Case
• Biotech Tells Chancery Drug Co. Abused Merger Prospects
• Crisis Management Lessons From The Parenting Playbook
• Elizabeth Holmes Loses Bid For Full 9th Circ. Rehearing
• Justices' Labcorp Questions Explore Class Cert. Tensions
• Ala. Legislature OKs TCJA Research Expense Decoupling
• Biotech Co. Accelerate Diagnostics Hits Ch. 11 With Sale Plan
• J&J Unit's Catheter Tying Policy Hurt Rival, Antitrust Jury Told
• FDA Gets Win In Eli Lilly Weight Loss Drug Shortage Fight
• Investors Fight J&J, Kenvue Bid To Nix IPO Fraud Suit
• Fertility Co. Accused Of Selling Bogus Tests Wasting Embryos
• Patent Examiners Tell GAO Quantity Beats Quality
• Fed. Circ. Clears Way For Sun Pharma Alopecia Drug
• Rite Aid Cleared For Quick Ch. 11 Sale Plans
• $525M Nuke Services Deal Faces Canada Competition Probe
• Insulet Pursues EOFlow's Finances After $60M Ruling
• Shionogi To Acquire Torii Pharma Through $1.1B Tender Offer
• Walgreens Wants 'Far-Fetched' Shareholder Suit Tossed
• 4 Legislative Proposals Reflect Growing Scrutiny Of Pharma IP
• Device Seller Asks For Probation In $2.4M Tax Evasion Case
• Orrick Hires Boston Duo For Life Sciences Practice
• Masimo Unloads Embattled Audio Unit In $350M Sale
• Adapting To Private Practice: From NY Fed To BigLaw
• Post-Ch. 11 Rite Aid Trustee Asks To Take Over Insurance Suit
• Medical Device Co. SeaStar Seeks Toss Of Shareholder Suit
• Quarles & Brady Adds New IP, Real Estate Partners
• Fed. Circ. Asks What Law Applies For Sleep Drug Injunction
• Haemonetics Sues Terumo Over Plasma Tech Patents
• Mylan Agrees To Keep Nausea Generics Off Market Until 2032
• Mistrial Declared On Punitive Damages In Bard Cancer Case
• Ex-CEO Can't Shake Conviction In COVID Test Kit Fraud Case
• 7 Considerations For Conducting Drug Clinical Trials Abroad
• Trade Secrets Emerge As Path For Cos. To Protect AI Works
• Top 3 Litigation Finance Deal-Killers, And How To Avoid Them
• Trump Orders FDA To Speed Up Drug Plant Approvals
• Gene-Editing Co. Synthego Hits Ch. 11 With Sights On A Sale
• DC Circ. Has Doubts About Narcolepsy Drug Appeal
• Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight
• 8th Circ. Backs Boehringer's Copyright Win Over Software Co.
• Regeneron, Amgen Open Drug 'Bundling' Trial In Del.
• PTAB Says It's Bedtime For Sleep Apnea Patent Claims
• Trump Admin Urges Dismissal Of States' Abortion Pill Suit
• Pharma Co. Escapes Investor Liver Drug Trial Suit, For Now
• Rite Aid Hits Bankruptcy Less Than A Year After Previous Ch. 11
• 5th Circ. Ruling Is Latest Signal Of Shaky Qui Tam Landscape
• Purdue Tells Justices 'Rigid' Fed. Circ. Rule Threatens Patents
• Exactech Committee Calls Foul On Ch. 11 Voting Packages
• How Attys Can Use A Therapy Model To Help Triggered Clients
• Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial
• High Court Won't Hear Challenge To Miss. Ban On Pot Ads
• Insulin Giants' Antitrust Victory On Shaky Ground At 2nd Circ.
• Boston Scientific, FDA Sued Over 'Unsafe' Spinal Implant
• Plaintiffs Seek Redo Over Sterilization Co.'s Trial Tactics
• Tax Case Can Proceed Despite Late Name Change, Court Says
• Fed. Circ. Gives MSN Short Pause For Entresto Appeal
• Ex-SCWorx CEO Seeks Sentencing Delay Over Restitution Row
• CR Bard Owes $20M In Ga. Ethylene Oxide Cancer Trial
• Faegre Drinker Lands Patent Team From Wilson Sonsini
• Goodwin Adds Scientist IP Partner From Cooley On West Coast
• 23andMe Says 1.3M Customers Have Asked To Delete Data
• Taxation With Representation: Goodwin, Haynes Boone
• 3 Steps For In-House Counsel To Assess Litigation Claims
• HHS Report Finds 'Serious Concerns' On Trans Care For Youth
• 5 Fed. Circ. Clashes To Watch This Month
• CR Bard Owes For Plant Neighbor's Illness, Jury Told
• Couple's J&J Pelvic Mesh Claims Too Late, 11th Circ. Affirms
• Publix Can't Slip 'Zero-Market Share' Opioid Claims
• PBMs Tell 6th Circ. Ohio's Pricing Case Belongs In Fed Court
• Senators Reintroduce Patent Eligibility, PTAB Reform Bills
• US Tells Justices Telemedicine Case Isn't Ideal For Eligibility
• J&J Talc Unit Says New Doc 'Key' To Talc Study Libel Suit
• Payment Math Dooms Sandoz Price-Fixing Deal With Florida
• J&J's Failed 3rd Try Casts Doubt On Use Of 'Texas Two-Step'
• Paul Hastings, GenapSys Settle Calif. Legal Malpractice Suit
• McCarter & English Fights Ex-Client's $1M Fee Reduction Bid
• Teaching College Students Makes Me A Better Lawyer